Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 9,560.00
+450.00 (4.94%)
Apr 16, 2026, 1:50 PM KST
Prestige BioPharma Market Cap
Prestige BioPharma has a market cap or net worth of 109.5 billion as of April 15, 2026. Its market cap has decreased by -27.58% in one year.
Market Cap
109.50B
Enterprise Value
198.53B
Revenue
19.02B
Ranking
n/a
PE Ratio
40.06
Stock Price
9,560.00
Market Cap Chart
Since May 28, 2021, Prestige BioPharma's market cap has decreased from 360.58B to 109.50B, a decrease of -69.63%. That is a compound annual growth rate of -21.65%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 15, 2026 | 109.50B | -29.11% |
| Dec 30, 2025 | 154.45B | -14.96% |
| Dec 30, 2024 | 181.61B | 59.39% |
| Dec 28, 2023 | 113.94B | 29.33% |
| Dec 29, 2022 | 88.10B | -64.84% |
| Dec 30, 2021 | 250.60B | -30.50% |
| May 28, 2021 | 360.58B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| MedPacto | 180.63B |
| Vaxcell-Bio Therapeutics | 179.55B |
| Macrogen | 177.58B |
| ENCell | 157.07B |
| Amicogen | 139.50B |
| iNtRON Biotechnology | 116.66B |
| CG Invites | 103.73B |
| Oncocross | 95.74B |